1.
Yao JC, Hassan M, Phan A, et al: One hundred years after ‘carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
2.
Allan B, Davis J, Perez E, et al: Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients. Eur J Pedatr Surg 2013;23,394-399.
3.
Anwar K, Desai M, Al-Bloushi N, et al: Prevalence and clinicopathological characteristics of appendiceal carcinoids in Sharjah (United Arab Emirates). World J Gastrointest Oncol 2014;6:253-256.
4.
Benedix F, Reimer A, Gastinger I, et al: Primary appendiceal carcinoma - epidemiology, surgery and survival: results of a German multi-center study. EJSO 2010;36:763-771.
5.
Boxberger N, Redlich A, Böger C, et al: Neuroendocrine tumors of the appendix in children and adolescents. Pediatr Blood Cancer 2013;60:65-70.
6.
Ellis L, Shale MJ, Coeman MP: Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 2010;105:2563-2569.
7.
In't Hoff KH, van der Wal HC, Kazemier G, et al: Carcinoid tumour of the appendix: an analysis of 1,485 consecutive emergency appendectomies. J Gastrointest Surg 2008;12:1436-1438.
8.
Hauso O, Gustafsson BI, Kidd M, et al: Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008;113:2655-2664.
9.
Lepage C, Rachet B, Coleman MP: Survival from malignant digestive endocrine tumors in England and Wales: a population based study. Gastroenterology 2007;132:899-904.
10.
Modlin IM, Lye KD, Kidd M: A five-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959.
11.
Quaedvlieg PF, Visser O, Lamers CB, et al: Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2,391 patients. Ann Oncol 2001;12:1295-1300.
12.
Tsai HJ, Wu CC, Tsai CR, et al: The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One 2013;8:e62487.
13.
Gouffon M, Iff S, Ziegler K, et al: Diagnosis and workup of 522 consecutive patients with neuroendocrine neoplasms in Switzerland. Swiss Med Wkly 2014;144:w13924.
14.
Hsu C, Rashid A, Xing Y, et al: Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype. J Surg Oncol 2013;107:136-143.
15.
Graham RPD, Williams NP, West KA: Primary epithelial tumours of the appendix in a black population: a review of cases. World J Gastroenterol 2009;15:1472-1474.
16.
Ito T, Sasano H, Tanaka M, et al: Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010;45:234-243.
17.
Scott A, Upadhyay V: Carcinoid tumors of the appendix in children in Auckland, New Zealand: 1965-2008. NZ Med J 2011;124:56-60.
18.
Zhang X, Ma L, Bao H, et al: Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study. BMC Endocr Disord 2014;14:54.
19.
Mullen JT, Savarese DMF: Carcinoid tumors of the appendix: a population-based study. J Surg Oncol 2011;104:41-44.
20.
Crea N, Pata G, Di Betta E, et al: High incidence of appendix carcinoid tumors among candidates for bariatric surgery: diagnostic and therapeutic implications. Obes Surg 2011;21:151-156.
21.
Gustaffson BI, Siddique L, Chan A, et al: Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy. Int J Oncol 2008;33:1121-1131.
22.
Niederle MB, Hackl M, Kaserer K, et al: Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010;17:909-918.
23.
Helland SK, Prosch AM, Viste A: Carcinoid tumours in the gastrointestinal tract - a population-based study from western Norway. Scand J Surg 2006;95:158-161.
24.
Lepage C, Bouvier AM, Manfredi S, et al: Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol 2006;101:2826-2832.
25.
García-Carbonero R, Capdevila J, Crespo-Herrero G, et al: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010;21:1794-1803.
26.
Ploeckinger U, Kloeppel G, Wiedenmann B, et al: The German NET registry: an audit on the diagnosis and therapy of neuroendocrine tumours. Neuroendocrinology 2009;90:349-363.
27.
Prommegger R, Obrist P, Ensinger C, et al: Retrospective evaluation of carcinoid tumors of the appendix in children. World J Surg 2002;26:1489-1492.
28.
Parkes SE, Muir KR, Sheyyab M, et al: Carcinoid tumours of the appendix in children 1957-1986: incidence, treatment and outcome. Br J Surg 1993;80:502-504.
29.
Kulkarni KP, Sergi C: Appendix carcinoids in childhood: long-term experience at a single institution in Western Canada and systematic review. Pediatr Int 2013;55:157-162.
30.
McGory ML, Maggard MA, Kang H, et al: Malignancies of the appendix: beyond case series reports. Dis Colon Rectum 2005;48:2264-2271.
31.
Landry CS, Woodall C, Scoggins, et al: Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system. Arch Surg 2008;143:664-670.
32.
Moertel CG, Dockerty MB, Judd ES: Carcinoid tumors of the vermiform appendix. Cancer 1968;21:270-278.
33.
McCusker ME, Cote TR, Clegg LX, et al: Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 2002;94:3307-3312.
34.
Niederle MB, Niederle B: Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist 2011;16:602-613.
35.
Goede AC, Caplin ME, Winslet MC: Carcinoid tumour of the appendix. Br J Surg 2003;90:1317-1322.
36.
Groth SS, Virnig BA, Al-Refaie WB, et al: Appendiceal carcinoid tumors: predictors of lymph node metastasis and the impact of right hemicolectomy on survival. J Surg Oncol 2011;103:39-45.
37.
Moertel CG, Weiland LH, Nagorney DM, et al: Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987;317:1699-1701.
38.
Stinner B, Rothmund M: Neuroendocrine tumours (carcinoids) of the appendix. Best Pract Res Clin Gastroenterol 2005;19:729-738.
39.
Deans GT, Spence RA: Neoplastic lesions of the appendix. Br J Surg 1995;82:299-306.
40.
O'Donnell ME, Carson J, Garstin WIH, et al: Surgical treatment of malignant carcinoid tumours of the appendix. Int J Clin Pract 2007;61:431-437.
41.
Shapiro R, Eldar S, Sadot E, et al: Appendiceal cracinoid at a large tertiary center: pathologic findings and long-term follow-up evaluation. Am J Surg 2011;201:805-808.
42.
Coursey CA, Nelson RC, Moreno RD, et al: Carcinoid tumours of the appendix: are these tumors identifiable prospectively on preoperative CT? Am Surg 2010;76:273-275.
43.
Debnath D, Rees J, Myint F: Are we missing diagnostic opportunities in cases of carcinoid tumors of the appendix? Surgeon 2008;6:266-272.
44.
Pickhardt PJ, Levy AD, Rohrmann CA, et al: Primary neoplasms of the appendix: radiologic spectrum of disease with pathologic correlation. Radiographics 2003;23:645-662.
45.
Virgone C, Cecchetto G, Alagio A, et al: Appendiceal neuroendocrine tumours in childhood: Italian TREP project. J Pediatr Gastroenterol Nutr 2014;58:333-338.
46.
Pape UF, Perren A, Niederle B, et al: ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012;95:135156.
47.
Prommegger R, Ensinger C, Adlassnig C, et al: Catestatin - a novel neuropeptide in carcinoid tumors of the appendix. Anticancer Res 2004;24:311-316.
48.
Modlin IM, Kidd M, Latich I, et al: Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed. Ann Surg 2006;244:52-60.
49.
O'Toole D, Grossman A, Gross D, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 2009;90:194-202.
50.
Klimstra DS, Arnold R, Capella C, et al: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System. Lyon, IARC, 2010.
51.
Sobin LH, Gospodarowicz MK, Wittekind C (eds): TNM Classification of Malignant Tumours. Chichester, Wiley and Blackwell, 2009.
52.
Rindi G, Klöppel G, Couvelard A, et al: TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-762.
53.
Tang LH, Shia J, Soslow RA, et al: Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol 2008;32:1429-1443.
54.
Volante M, Daniele L, Asioli F, et al: Tumor staging but not grading is associated with adverse clinical outcome in neuroendocrine tumors of the appendix. Am J Surg Pathol 2013;37:606-612.
55.
Washington MK, Tang LH, Berlin J, et al: Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the appendix. Arch Pathol Lab Med 2010;134:171-175.
56.
Tang LH: Epithelial neoplasms of the appendix. Arch Pathol Lab Med 2010;134:1612-1620.
57.
Moertel CG, Weiland LH, Telander RL: Carcinoid tumor of the appendix in the first two decades of life. J Pediatr Surg 1990;25:1073-1075.
58.
Fornaro R, Frascio M, Sticchi S, et al: Appendectomy or right hemicolectomy in the treatment of appendiceal carcinoid tumors? Tumori 2007;93:587-590.
59.
Alexandraki KI, Griniatsos J, Bramis KI, et al: Clinical value of right hemicolectomy for appendiceal carcinoids using pathologic criteria. J Endocrinol Invest 2011;34:255-259.
60.
Bamboat ZM, Berger DL: Is right hemicolectomy for 2.0-cm appendiceal carcinoids justified? Arch Surg 2006;141:349-352.
61.
Dunn JP: Carcinoid tumours of the appendix: 21 cases, with a review of the literature. NZ Med J 1982;95:73-76.
62.
Rossi G, Valli R, Bertolini F, et al: Does mesoappendix infiltration predict a worse prognosis in incidental neuroendocrine tumors of the appendix? A clinicopathologic and immunohistochemical study of 15 cases. Am J Clin Pathol 2003;120:706-711.
63.
Henderson L, Fehily C, Folaranmi S, et al: Management and outcome of neuroendocrine tumours of the appendix - a two centre UK experience. J Pediatr Surg 2014;49:1513-1517.
64.
Arnold R, Chen YJ, Costa F, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumours: follow-up and documentation. Neuroendocrinology 2009;90:227-233.
65.
Murray SE, Lloyd RV, Sippel RS, et al: Post-operative surveillance of small appendiceal carcinoid tumors. Am J Surg 2014;207:342-345.
66.
Lamarca A, Nonaka D, Lopez Escola C, Hubner RA, OʼDwyer S, Chakrabarty B, Fulford P, Valle JW: Appendiceal goblet cell carcinoids: management considerations from a reference peritoneal tumour service centre and ENETS Centre of Excellence. Neuroendocrinology DOI:10.1159/000440725.
67.
Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 2016;103:119-124.
68.
Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for neuroendocrine neoplasm of the jejunum and ileum. Neuroendocrinology 2016;103:125-138.
69.
Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, Ruszniewski P, Sundin A, Weber W, Zheng-Pei Z, Taal B, Pascher A; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology 2016;103:139-143.
70.
Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016;103:153-171.
71.
Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016;103:172-185.
72.
Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; all other Vienna Consensus Conference participants: ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 2016;103:186-194.
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.